Andrea Malaspina

Andrea Malaspina

Professor of Neurology

Andrea Malaspina is a Professor of Neurology and the Clinical Academic Lead of the Queen Square Motor Neuron Disease Centre, Institute of Neurology, UCL. After obtaining a PhD in Molecular Neurobiology from Imperial College London, he has worked as a Consultant Neurologist at Barts Health and founded the local MND Care and Research Centre with an active role in Clinical Neurology and research interests in neuromuscular and motor cell disorders. In 2009, he founded the Barts Health MND Care and Research Centre. In 2012, he took up a formal academic appointment as Clinical Senior Lecturer with the Barts and The London Medical School and as Professor of Neurology from 2019. He has been responsible for MND research in the North-Thames LCRN and has led the Neurodegeneration Research Group at the Blizard Institute, London.

Connect
Connect trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Recruiting
Phase iii

ADORE Trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more